Approved indications:

• Adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more conventional disease-modifying antirheumatic drugs (DMARDs).
• Adults with polymyalgia rheumatica who have had an inadequate response to corticosteroids or cannot tolerate a corticosteroid taper.
• Patients with active polyarticular juvenile idiopathic arthritis who weigh at least 63 kg.

Off-label uses and evidence:

• Sarilumab has been studied in conditions such as severe COVID-19 pneumonia and giant cell arteritis, but Kevzara is not FDA-approved for these uses; any off-label use relies on limited clinical data and specialist judgment about risks and benefits.

Efficacy expectations and comparison:

• In rheumatoid arthritis, many patients notice less joint pain and stiffness within a few weeks, with maximal improvements in function and quality of life developing over several months; long-term use helps slow structural joint damage.
• In polymyalgia rheumatica, Kevzara plus a rapid steroid taper leads to more patients achieving sustained remission and a much lower cumulative steroid dose than with prolonged steroid taper alone, with remission typically assessed around 12 weeks and maintained over 1 year.
• In polyarticular juvenile idiopathic arthritis, trials show reductions in the number of active joints and disease flares over the first few months at the approved weight-based dose.
• For arthritis indications, its overall effectiveness is broadly similar to other biologic DMARDs (such as TNF inhibitors and other IL-6 inhibitors), while its distinctive role is being the first FDA-approved biologic steroid-sparing option for polymyalgia rheumatica.

Typical dosing and administration:

• For adults with rheumatoid arthritis or polymyalgia rheumatica, the recommended dose is 200 mg injected under the skin once every 2 weeks; in polymyalgia rheumatica this is started together with a tapering course of oral corticosteroids and may later be continued alone.
• For patients with active polyarticular juvenile idiopathic arthritis who weigh at least 63 kg, the recommended dose is also 200 mg subcutaneously every 2 weeks, used alone or with conventional DMARDs.
• Kevzara is supplied as single-use prefilled syringes or pens; injections are given into the front of the thigh or abdomen (or the outer upper arm if given by a caregiver), rotating sites each time, and can be taken with or without food at any convenient, consistent time of day.

Dose adjustments and special instructions:

• If blood tests show low neutrophils, low platelets, or elevated liver enzymes, the dose may be reduced from 200 mg to 150 mg every 2 weeks or temporarily held, according to the prescriber’s guidance.
• Treatment should not be initiated in patients with very low baseline neutrophil or platelet counts or significantly elevated liver enzymes, or in those with active serious infections.
• Before starting, patients are usually screened for tuberculosis and other infections, and baseline blood counts, liver tests, and lipid levels are obtained.

Missed-dose guidance:

• If a dose is missed, inject it as soon as you remember unless it is close to the next scheduled dose; do not inject two doses at once, and contact your prescriber or pharmacist for specific timing advice if you are unsure.

Overdose:

• Taking more than the prescribed amount can increase the risk of serious side effects; if an overdose is suspected, contact a healthcare provider or Poison Control (1-800-222-1222 in the U.S.) right away, or seek emergency care if severe symptoms occur.

Common side effects:

• Injection-site reactions (redness, itching) and mild upper respiratory symptoms (nasal congestion, sore throat, runny nose) are among the most frequent and are usually mild to moderate.
• Other common effects include urinary tract infections, nasopharyngitis or upper respiratory tract infections, headache, constipation, mild rash or itching, muscle aches, and fatigue.
• Laboratory changes are frequent, including increased liver enzymes, higher cholesterol and triglycerides, and lower neutrophil or platelet counts; these are usually detected on routine blood tests.

Serious or rare adverse effects needing urgent care:

• Serious infections (such as pneumonia, tuberculosis, invasive fungal infections, or shingles) that may cause fever, chills, cough, shortness of breath, painful rash, or feeling very ill.
• Severe allergic reactions with shortness of breath, chest pain, dizziness or fainting, or swelling of the lips, tongue, face, or throat, or moderate to severe abdominal pain with vomiting.
• Gastrointestinal perforation (a hole in the stomach or intestines), particularly in people with diverticulitis or on NSAIDs or steroids, which can present as sudden severe abdominal pain, fever, or blood in the stool.

Warnings and precautions:

• Should not be started in people with active serious infections; patients are typically screened for tuberculosis and sometimes hepatitis before treatment and monitored closely for infection symptoms.
• Use is not recommended in active hepatic disease or significant hepatic impairment; liver enzymes, complete blood counts, and lipids need regular monitoring.
• In pregnancy and breastfeeding, human experience is limited; use is generally reserved for situations where the expected benefit justifies potential risks, with shared decision-making.
• Caution is advised in older adults and in people with recurrent infections, diverticulitis, uncontrolled diabetes, or other conditions that raise infection or perforation risk.
• Live vaccines should be avoided during therapy; routine immunizations should ideally be updated before starting Kevzara.

Comparative safety:

• Like other biologic DMARDs, Kevzara carries a boxed warning for serious infections, but long-term rheumatoid arthritis data have not shown new or unexpected safety signals.
• Compared with TNF inhibitors, IL-6 inhibitors such as Kevzara more often cause laboratory abnormalities (neutropenia, elevated liver enzymes, lipid changes) and have a recognized, though uncommon, risk of gastrointestinal perforation.

Reporting side effects and safety updates:

• Side effects can be reported by patients or clinicians to the FDA MedWatch program (online or by calling 1-800-FDA-1088) or directly to the manufacturer’s support line.
• Current safety information, including new warnings, is provided in the Medication Guide that comes with the drug and on FDA and manufacturer websites.

Drug and supplement interactions:

• By blocking IL-6 and reducing inflammation, Kevzara can restore CYP450 enzyme activity and lower blood levels of drugs metabolized by these pathways; medicines that may be affected include warfarin and other certain blood thinners, some statins, oral contraceptives, theophylline, and various antidepressants or antipsychotics, so closer monitoring or dose adjustments may be needed.
• Use with other biologic DMARDs or JAK inhibitors is generally avoided because of additive immunosuppressive effects and higher infection risk.
• Concomitant use with conventional nonbiologic DMARDs (such as methotrexate) or corticosteroids is common but increases infection risk, so careful monitoring is required.
• No specific food interactions are known; alcohol should be limited, especially in people with liver disease or those taking other hepatotoxic medications.

Vaccines, procedures, and imaging:

• Live vaccines (such as MMR, varicella, some shingles vaccines, and intranasal flu vaccine) should not be given during Kevzara therapy; inactivated vaccines are generally acceptable but may be somewhat less effective.
• Ideally, routine vaccinations are brought up to date before starting Kevzara; for planned surgery, rheumatology or surgical teams may adjust the timing of doses or briefly interrupt therapy.
• Kevzara can suppress C-reactive protein and other inflammatory markers, which may blunt typical lab signs of infection or inflammation in diagnostic workups.

Conditions and co-medications requiring caution or avoidance:

• Active serious infections, untreated latent tuberculosis, or a history of frequent or severe infections.
• Known diverticulitis or previous gastrointestinal perforation, uncontrolled diabetes, or other conditions that substantially raise infection or perforation risk.
• Moderate to severe hepatic impairment or persistently elevated liver enzymes.
• Pregnancy or breastfeeding without careful risk–benefit assessment, and older or frail patients who may be more vulnerable to adverse effects.

Monitoring needs:

• Baseline and periodic complete blood counts, liver function tests, and lipid panels (typically at baseline, 4–8 weeks after initiation, then every 3–6 months as clinically indicated).
• Screening for tuberculosis (and when appropriate, hepatitis B and C) before therapy, with ongoing clinical monitoring for infection symptoms, gastrointestinal complaints, and other adverse effects throughout treatment.

Q: What conditions does Kevzara treat?
A: Kevzara is used to treat adults with moderately to severely active rheumatoid arthritis or polymyalgia rheumatica and patients who weigh at least 63 kg with active polyarticular juvenile idiopathic arthritis.

Q: How long does it take for Kevzara to start working?
A: Some people notice less pain and stiffness within a few weeks, but it can take several months of regular injections to see the full benefit.

Q: Can I use Kevzara with methotrexate or steroids?
A: Yes, Kevzara is often used with methotrexate or other conventional DMARDs for arthritis, and with a tapering course of corticosteroids in polymyalgia rheumatica, but this combination can increase infection risk and needs careful monitoring.

Q: What should I know about vaccines while on Kevzara?
A: Live vaccines should be avoided during Kevzara treatment, so most vaccinations should be brought up to date before starting; inactivated vaccines are usually allowed but may be less effective, so always check with your prescriber.

Q: What happens if I get sick or need surgery while using Kevzara?
A: If you develop signs of infection or are scheduled for surgery, you should contact your prescriber promptly, as Kevzara may need to be delayed or temporarily stopped until the infection or procedure is safely managed.

Q: Can I inject Kevzara myself at home?
A: After training from a healthcare professional, many patients or caregivers can use the prefilled syringe or pen at home every 2 weeks, following the instructions for injection sites, storage, and disposal.

Storage:

• Keep Kevzara prefilled syringes or pens in the refrigerator at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light.
• Do not freeze or shake; let the device warm to room temperature before injection, without using external heat sources.
• If needed, Kevzara may be stored at room temperature up to 77°F (25°C) for a single period of up to 14 days, then must be used or discarded and not returned to the refrigerator.

Handling and disposal:

• Each syringe or pen is single-use; do not reuse it even if some liquid remains.
• Immediately place used needles, syringes, or pens into a puncture-resistant FDA-cleared sharps container rather than household trash or recycling.
• When the sharps container is almost full, follow local or pharmacy instructions for disposal (such as drug or sharps take-back programs); do not flush medicines or sharps down the toilet or sink.

Other tips:

• Keep Kevzara and sharps containers out of the reach of children and pets, and do not use a device if the solution is cloudy, discolored, contains particles, or the pen/syringe appears damaged.